Use Case UK

UK use case scenarios tagging, tracking and reverse supply chain modeling in Leeds, England

For several years there has been a discussion about whether or not 2-D-barcodes could be helpful for the fight against counterfeiting. 2-D-barcodes on packets and blisters could help consumers to trace their products back and to gain insurances whether or not they are dealing with an original and potent product or with a counterfeited product, which might be potentially harmful. It would also help manufacturers to make a decision to recall certain charges and leave others in the shelves. Applications to read barcodes and 2-D-barcodes are available for most mobile phones for free from the Internet.
However, so far no services are available. GS1 a UK standardization company is strongly supporting the move and manufacturers and the National Health Service do not deny the potential benefit for all user groups.
The risks of medication not being properly tagged and encoded caught the public’s eye in 2009 when famous actor Dennis’ Quaid got into a life threatening situation through an accidental overdose which could have easily been avoided if the drug information could have been read out by the dispensing nurse. The nurse did not realize that the concentration of the drug she was dispensing was the adult dose and not the children’s prescription. Medichem Leeds is a Pharmacy Whole Seller from Leeds, UK who have been involved in research on tagging and tracking before.

Medichem Leeds wants to tag 10000 medication and pharmaceutical products such as Insulin Pens over a test period of 6-8 months. Medichem Leeds will follow GS1 standards and 2-D-Barcode tags will be attached to their retail products but the idea is to manufacture generic drugs for the European market fitted with barcodes on the package and the blisters containing the medication to enable end-users to use FI-technology to scan and identify the drugs at any time, any how and anywhere. This has become even more interesting as 4G networks are going to be rolled out in Leeds and the UK already in the coming year. Medichem Leeds will also create a repository and start to deposit product related information, which then can be accessed by the users. There will be different use case scenarios running through alpha and beta versions of prototyping:

Experimentation Site:

Medichem Leeds is a research conducting SME with 25 employees in Leeds, England, UK. The pharmacy has partly retail business and partly wholesale business with medication, medical equipment and consumables delivered to practices and hospitals. Medichem Leeds has their own production line in preparation and is aiming to sell their own branded pharmaceuticals manufactured in Asia within the next year on the European market.

Case 1:

Medication in the UK is normally repacked in the retail business. Currently the generic package is fitted with a printed or handwritten sticker attached to the pack by the pharmacist. For -testing 2-D-Barcode stickers will simply be attached to the prescribed medication boxes and end-users will be able to scan the tag and will receive information on when they purchased the drugs, which member of staff served them, how much they were charged, etc.

Case 2:

Medical products such as Insulin Pens, Glucometers, blood pressure machines, etc. will be fitted with a tag and users will be able to scan their product with their smart phones. They will be able to watch a video describing the use of the product. Naturally they will be able to replay the video as many times as they like. This will replace in some cases several doctor’s visits or visit to the pharmacy. In the α version the products are simply tagged with a tag which will be printed at the pharmacy when the customer purchases the product. The video clips might be available from the manufacturer or will be produced as part of the project (which is stall subject to negotiations).

Case 3:

As a next step in the development Medichem Leeds will use the barcodes on pharmaceuticals and medical products, which are created in particular for Medichem Leeds and will conduct -trials.

Use case Specifications

StandardizationThe project will utilize and follow existing GS1 standards
FI-PPP GEsUse case relevant GEs are the IOT GE to link the printer and reader devices with the database to store information in real time and the Data/Context Management GE in order to integrate information from different sources.
Usage specific ApplicationsWill be necessary to identify the members of staff who processed the order and to build the database on a local private cloud. The extent of the usage specific application depends on the extent and quality of the GEs available in April 2013.
Sample SizeIn the a-phase of each use case we are expecting a sample size of n=200-1000 (medical devices are sold in smaller numbers than medication). Once the b phase commences we expect the process to easily reach thousands and ultimately hundred thousands of tags.

The development process will follow the double-looped approach outlined in the technical part of the FI-STAR proposal. The project will follow existing GS1 standards. Medichem Leeds will receive support for the development of cloud based services from Celestor Ltd. Medichem Leeds will appoint programmers and will contribute staff to conduct the study. Ethical approval is not needed but for the avoidance of any doubt we can apply for ethical approval once the grant has been allocated and rectified.Medichem Leeds will collaborate with all other FI-STAR experimentation sites and also feed into the community building activities. Medichem Leeds will be very active in terms of dissemination and distribution.